OSR Health, Inc.
OSRHHealthcareNASDAQBiotechnology · Last scanned Jul 22, 2026
Scan Results
Daily timeframePart of the healthcare sector, OSR Health, Inc. (OSRH) is listed under Biotechnology. At a $15.4M market cap, OSR Health, Inc. ranks as a micro-cap company within healthcare. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1.
Market Cap
$15.4M
Beta
0.72
P/E (TTM)
14.58
P/E (Fwd)
—
EPS (TTM)
$0.03
EPS (Fwd)
—
ROE
-14.7%
ROA
-6.9%
Cash
$1.6M
Total Debt
$5.0M
Free CF
$1.4M
52W Change
-57.5%
Annual Financials
Cash vs Debt
Where OSRH stands vs its 150-day and 200-day moving averages
As of the July 9, 2026 close, OSRH finished 41.51% below its 150-day moving average ($0.53) and 43.64% below its 200-day moving average ($0.55). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is OSRH overbought or oversold?
At the July 9, 2026 close, OSRH's RSI(14) was 29.1, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $1.6M in cash, though total debt stands at $5.0M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $1.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -14.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Investors considering OSR Health, Inc. should weigh the typical risks associated with OSRH's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing OSRH's risk profile alongside its fundamentals and technical indicators provides a more complete picture.